-
Feb 7, 2024, 08:09 AM
by
Full story
-
Feb 7, 2024, 08:09 AM
by
Full story
-
Feb 7, 2024, 08:09 AM
by
Full story
-
Feb 7, 2024, 08:09 AM
by
Game-Changing ‘Audit Trail Review’ Application Secures ACDM 2024 Awards Nomination for CluePoints
RBQM Leader Shortlisted for Accolade for Innovation in the Management of Clinical Data
Full story
-
Feb 7, 2024, 01:00 AM
by
User Not Found
Bio-IT World | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.
Full story
-
Feb 6, 2024, 09:01 AM
by
Datavant’s privacy-preserving record linkage technology will allow Verisense Health’s digital health data to generate richer patient insights.
Full story
-
Feb 6, 2024, 09:01 AM
by
Azenta, Inc has announced the launch of the BioArc™ Ultra, a breakthrough, automated solution for high-density, eco-friendly ultracold sample management, designed to provide a new level of performance.
Full story
-
Feb 6, 2024, 09:01 AM
by
Azenta Life Sciences has announced that it will display a range of productivity-enhancing consumables, instruments, and automated sample storage products at SLAS 2024 in Boston, USA from February 5 - 7.
Full story
-
Feb 6, 2024, 09:01 AM
by
Integrated DNA Technologies and Element Biosciences are bolstering its partnership to equip AVITI users with differentiated NGS tools.
Full story
-
Feb 6, 2024, 01:00 AM
by
User Not Found
Bio-IT World | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.
Full story
-
Feb 5, 2024, 09:03 AM
by
Full story
-
Feb 2, 2024, 09:19 AM
by
Lixe Biotechnology announced the dosing of the first patient in its Phase 1b/2 clinical trial to assess the efficacy of its LB-100 lead molecule with GSK's PD-1-blocking monoclonal antibody, dostarlimab-gxly, in the treatment of ovarian clear cell carcinoma.
Full story
-
Feb 2, 2024, 09:19 AM
by
Lindus Health Introduces Bespoke “All-In-One CRO for Digital Therapeutics” Solution to Companies in the Space Streamline Clinical Trials
Full story
-
Feb 2, 2024, 09:19 AM
by
NADMED has announced an innovative technology designed for effortless extracting and measuring all four NADs and two glutathiones.
Full story
-
Feb 1, 2024, 08:53 AM
by
AppOmni, the pioneer of SaaS security posture management (SSPM), proudly announces the establishment of a new data centre in Sydney, Australia, hosted by Google Cloud Platform (GCP).
This new initiative brings AppOmni’s comprehensive SaaS security solutions to any organisation—private or public—required to comply with Australia’s data sovereignty regulations, including the Privacy Act and the Australian Privacy Principles.
As AppOmni continues its global expansion efforts, Australia remains a strategic location for the company. The new data centre helps address a growing need in the APAC region to counter sophisticated threats targeting SaaS applications. These concerns are echoed by the 25% of Fortune 100 companies that already trust AppOmni to secure their SaaS ecosystems.
Full story
-
Feb 1, 2024, 01:00 AM
by
User Not Found
Bio-IT World | Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health have created a next-generation sequencing (NGS) technology that employs oligonucleotides (oligos)—short single strands of synthetic DNA—as bait for relevant targets of detection.
Full story
-
Jan 31, 2024, 08:28 AM
by
Devens, MA, US / 30th January 2023 / Sciad Newswire / Watson-Marlow Fluid Technology Solutions (WMFTS), a leader in peristaltic pumps and associated fluid path technologies, will showcase its diverse product range specially designed for medical devices and diagnostic instruments at MD&M West in Anaheim, CA, from February 6-8.
Full story
-
Jan 31, 2024, 08:28 AM
by
This collaboration allows payers to make processes such as prior authorization more efficient; especially critical given the new requirements for faster turnaround times. Digitizing faxed documents and applying technologies such as AI and NLP to mine data cuts back on manual steps, reducing administrative burden and costs.
Full story
-
Jan 31, 2024, 08:28 AM
by
Currax Pharmaceuticals announces the first patient screened and accepted into the CONTRAVE® INFORMUS Cardiovascular Outcomes Trial (NB-CVOT3).
Full story
-
Jan 31, 2024, 08:28 AM
by
Qlucore, a leader in software development for precision cancer diagnostics, has taken the final major step in the process towards a CE-marked medical device for in-vitro diagnostics by submitting the technical documentation to a Notified Body. The CE marked product, Qlucore Diagnostics, is due to be launched in February 2025.
Full story